183 related articles for article (PubMed ID: 31549969)
1. The newest treatments for uveal melanoma.
Luke JJ
Clin Adv Hematol Oncol; 2019 Sep; 17(9):490-493. PubMed ID: 31549969
[No Abstract] [Full Text] [Related]
2. New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma.
Barker CA; Salama AK
J Natl Compr Canc Netw; 2018 May; 16(5S):646-650. PubMed ID: 29784747
[TBL] [Abstract][Full Text] [Related]
3. Uveal vs. cutaneous melanoma. Origins and causes of the differences.
Belmar-Lopez C; Mancheno-Corvo P; Saornil MA; Baril P; Vassaux G; Quintanilla M; Martin-Duque P
Clin Transl Oncol; 2008 Mar; 10(3):137-42. PubMed ID: 18321815
[TBL] [Abstract][Full Text] [Related]
4. [Advances in uveal melanoma].
Piperno-Neumann S; Desjardins L
Rev Prat; 2014 Jan; 64(1):83-4. PubMed ID: 24649554
[No Abstract] [Full Text] [Related]
5. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy.
Wagner SN; Wagner C; Schultewolter T; Goos M
Cancer Immunol Immunother; 1997 Jun; 44(4):239-47. PubMed ID: 9222283
[TBL] [Abstract][Full Text] [Related]
7. [MBD4 inactivation induces a new mutator phenotype in cancers].
Rodrigues M; Mobuchon L; Houy A; Derrien AC; Stern MH
Bull Cancer; 2018 Sep; 105(9):736-737. PubMed ID: 30032956
[No Abstract] [Full Text] [Related]
8. The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas.
Makohon-Moore AP; Lipson EJ; Hooper JE; Zucker A; Hong J; Bielski CM; Hayashi A; Tokheim C; Baez P; Kappagantula R; Kohutek Z; Makarov V; Riaz N; Postow MA; Chapman PB; Karchin R; Socci ND; Solit DB; Chan TA; Taylor BS; Topalian SL; Iacobuzio-Donahue CA
Clin Cancer Res; 2021 Mar; 27(5):1516-1525. PubMed ID: 33323400
[TBL] [Abstract][Full Text] [Related]
9. Update on Metastatic Uveal Melanoma: Progress and Challenges.
Spagnolo F; Picasso V; Spano L; Tanda E; Venzano C; Queirolo P
BioDrugs; 2016 Jun; 30(3):161-72. PubMed ID: 27000042
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
11. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
12. An ocular melanoma-associated antigen. Molecular characterization.
Wang MX; Earley JJ; Shields JA; Donoso LA
Arch Ophthalmol; 1992 Mar; 110(3):399-404. PubMed ID: 1339263
[TBL] [Abstract][Full Text] [Related]
13. [Reaction of leukocyte migration inhibition in patients with uveal melanoblastoma].
Nifontova TP
Vopr Onkol; 1986; 32(4):57-61. PubMed ID: 3705529
[TBL] [Abstract][Full Text] [Related]
14. Pathology and genetics of uveal melanoma.
Griewank KG; Murali R
Pathology; 2013 Jan; 45(1):18-27. PubMed ID: 23222249
[TBL] [Abstract][Full Text] [Related]
15. The Ashton Lecture. Uveal melanoma: the past, the present and the future.
Rennie IG
Eye (Lond); 1997; 11 ( Pt 2)():255-64. PubMed ID: 9349422
[No Abstract] [Full Text] [Related]
16. [Current developments concerning malignant skin melanoma].
Dargent M
Maroc Med; 1972 Oct; 52(561):571-86. PubMed ID: 4667467
[No Abstract] [Full Text] [Related]
17. Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy.
Star P; Goodwin A; Kapoor R; Conway RM; Long GV; Scolyer RA; Guitera P
Eur J Cancer; 2018 Mar; 92():48-53. PubMed ID: 29413689
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous melanoma and its relation to melanoma of the uveal tract.
Noyes WD
Surv Ophthalmol; 1978; 23(2):143-5. PubMed ID: 705615
[TBL] [Abstract][Full Text] [Related]
19. [THE BRAF MUTATION AND THE POSSIBILITIES OF UVEAL MELANOMA METASTASING PROGNOSTIC MARKERS IDENTIFICATION].
Horkovičová K; Markus J; Krčová I; Babál P; Kobzová D; Smolková B
Cesk Slov Oftalmol; 2016; 72(4):149-156. PubMed ID: 27860480
[TBL] [Abstract][Full Text] [Related]
20. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
